High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 12, 2010, Pages 1929-1935

  Chung, Hyun Woo ^a   Lee, Eun Jeong ^b   Cho, Yo Han ^a   Yoon, So Young ^a   So, Young ^a   Kim, Sung Yong ^a   Lee, Mark Hong ^a   Kim, Jeong Hwan ^a   Lee, Sun Young ^a   Sung, In Kyung ^a   Park, Hyung Seok ^a   Yoo, Moon Won ^a   Lee, Kyung Yung ^a  

^a Konkuk University Hospital   (South Korea)

^b School of Medicine   (South Korea)

Author keywords

FDG; Metastatic gastric adenocarcinoma; PET CT; Prognosis

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISTANT METASTASIS; FEMALE; HUMAN; MALE; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78649318716     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0852-5     Document Type: Article

References (29)

1. SR Alberts A Cervantes CJ van de Velde 2003 Gastric cancer: epidemiology, pathology and treatment Ann Oncol 14 2 ii31 ii36 10.1093/annonc/mdg726 12810455
2. C Are JF Hsu RA Ghossein H Schoder JP Shah AR Shaha 2007 Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas Ann Surg Oncol 14 3210 3215 10.1245/s10434-007-9531-4 10.1245/s10434-007-9531-4 17713821 (Pubitemid 47594286)
3. P Bertuccio L Chatenoud F Levi D Praud J Ferlay E Negri, et al. 2009 Recent patterns in gastric cancer: a global overview Int J Cancer 125 666 673 10.1002/ijc.24290 1:CAS:528:DC%2BD1MXmsleqsL4%3D 10.1002/ijc.24290 19382179
4. JB Bomanji DC Costa PJ Ell 2001 Clinical role of positron emission tomography in oncology Lancet Oncol 2 157 164 1:STN:280:DC%2BD387ntFeltg%3D%3D 10.1016/S1470-2045(00)00257-6 11902566 (Pubitemid 33585927)
5. RJ Cerfolio AS Bryant 2006 Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival Ann Thorac Surg 82 391 394 10.1016/j.athoracsur.2006.03.045 10.1016/j.athoracsur.2006.03.045 16863735 discussion 394-5 (Pubitemid 44080040)
6. J Chen JH Cheong MJ Yun J Kim JS Lim WJ Hyung, et al. 2005 Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography Cancer 103 2383 2390 10.1002/cncr.21074 10.1002/cncr.21074 15856477 (Pubitemid 40686585)
7. AE Dassen DJ Lips CJ Hoekstra JF Pruijt K Bosscha 2009 FDG-PET has no definite role in preoperative imaging in gastric cancer Eur J Surg Oncol 35 449 455 10.1016/j.ejso.2008.11.010 1:STN:280:DC%2BD1M3ltlOjsw%3D%3D 19147324
8. LF de Geus-Oei D Vriens HW van Laarhoven WT van der Graaf WJ Oyen 2009 Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review J Nucl Med 50 1 43S 54S 10.2967/jnumed.108.057224 10.2967/jnumed.108.057224 19403879
9. F Di Fabio C Pinto FL Rojas Llimpe S Fanti P Castellucci C Longobardi, et al. 2007 The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab Gastric Cancer 10 221 227 10.1007/s10120-007-0438-3 1:CAS:528:DC%2BD2sXhsVGgt7rI 10.1007/s10120-007-0438-3 18095077 (Pubitemid 350308171)
10. JL Dickson D Cunningham 2004 Systemic treatment of gastric cancer Eur J Gastroenterol Hepatol 16 255 263 1:CAS:528:DC%2BD2cXjtlCkt74%3D 10.1097/00042737-200403000-00003 15195888
11. RJ Downey T Akhurst M Gonen A Vincent MS Bains S Larson, et al. 2004 Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection J Clin Oncol 22 3255 3260 10.1200/JCO.2004.11.109 10.1200/JCO.2004.11.109 15310769 (Pubitemid 41103680)
12. E Garin F Le Jeune A Devillers M Cuggia AS de Lajarte-Thirouard C Bouriel, et al. 2009 Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors J Nucl Med 50 858 864 10.2967/jnumed.108.057505 1:CAS:528:DC%2BD1MXnvF2rurY%3D 10.2967/jnumed.108. 057505 19443590
13. E Han W Choi Y Chung, et al. 2009 Comparison between FDG uptake and clinicopathologic and immunohistochemical parameters in pre-operative PET/CT scan of primary gastric carcinoma Nucl Med Mol Imaging 43 26 34
14. RJ Hicks 2009 Role of 18F-FDG PET in assessment of response in non-small cell lung cancer J Nucl Med 50 1 31S 42S 10.2967/jnumed.108.057216 1:CAS:528:DC%2BD1MXmtFahsb0%3D 10.2967/jnumed.108.057216 19380411
15. K Higashi K Ito Y Hiramatsu T Ishikawa T Sakuma I Matsunari, et al. 2005 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study J Nucl Med 46 267 273 15695786
16. SA Hundahl HR Menck EG Mansour DP Winchester 1997 The national cancer data base report on gastric carcinoma Cancer 80 2333 2341 1:STN:280: DyaK1c%2Fmslaitw%3D%3D 10.1002/(SICI)1097-0142(19971215)80:12<2333::AID- CNCR15>3.0.CO;2-V 9404711 (Pubitemid 28007405)
17. SK Kim KW Kang JS Lee HK Kim HJ Chang JY Choi, et al. 2006 Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer Eur J Nucl Med Mol Imaging 33 148 155 10.1007/s00259-005-1887-8 10.1007/s00259-005-1887-8 16228236 (Pubitemid 43152881)
18. Y Kitagawa K Sano S Nishizawa M Nakamura T Ogasawara N Sadato, et al. 2003 FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer Eur J Nucl Med Mol Imaging 30 63 71 10.1007/s00259-002-0978-z 1:CAS:528: DC%2BD38XpsV2iu7w%3D 10.1007/s00259-002-0978-z 12483411 (Pubitemid 36692894)
19. J Lee T Lim JE Uhm KW Park SH Park SC Lee, et al. 2007 Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann Oncol 18 886 891 10.1093/annonc/mdl501 1:STN:280:DC%2BD2s3ns1Klsg%3D%3D 10.1093/annonc/mdl501 17298958 (Pubitemid 47054086)
20. E Mochiki H Kuwano H Katoh T Asao N Oriuchi K Endo 2004 Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer World J Surg 28 247 253 10.1007/s00268-003-7191-5 10.1007/s00268-003-7191-5 14961197 (Pubitemid 38375523)
21. K Ott K Herrmann F Lordick H Wieder WA Weber K Becker, et al. 2008 Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study Clin Cancer Res 14 2012 2018 10.1158/1078-0432.CCR-07-0934 1:CAS:528:DC%2BD1cXkt1akur0%3D 10.1158/1078-0432.CCR-07-0934 18381939 (Pubitemid 351551110)
22. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
23. CE Reed DH Harpole KE Posther SL Woolson RJ Downey BF Meyers, et al. 2003 Results of the American college of surgeons oncology group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer J Thorac Cardiovasc Surg 126 1943 1951 10.1016/j.jtcvs.2003.07.030 10.1016/j.jtcvs.2003.07.030 14688710 (Pubitemid 38020756)
24. G Rosati D Ferrara L Manzione 2009 New perspectives in the treatment of advanced or metastatic gastric cancer World J Gastroenterol 15 2689 2692 1:CAS:528:DC%2BD1MXpsF2rtb4%3D 10.3748/wjg.15.2689 19522017
25. A Stahl K Ott WA Weber K Becker T Link JR Siewert, et al. 2003 FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings Eur J Nucl Med Mol Imaging 30 288 295 10.1007/s00259-002-1029-5 1:CAS:528:DC%2BD3sXms1Cmsw%3D%3D 10.1007/s00259-002- 1029-5 12552348
26. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
27. M Trumper PJ Ross D Cunningham AR Norman R Hawkins M Seymour, et al. 2006 Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials Eur J Cancer 42 827 834 10.1016/j.ejca.2005.08.044 1:CAS:528:DC%2BD28XksVOitLs%3D 10.1016/j.ejca.2005.08.044 16466913
28. HL van Westreenen M Westerterp PM Bossuyt J Pruim GW Sloof JJ van Lanschot, et al. 2004 Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer J Clin Oncol 22 3805 3812 10.1200/JCO.2004.01.083 10.1200/JCO.2004.01.083 15365078 (Pubitemid 41095222)
29. T Yoshioka K Yamaguchi K Kubota T Saginoya T Yamazaki T Ido, et al. 2003 Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer J Nucl Med 44 690 699 1:CAS:528:DC%2BD3sXkt1KisL8%3D 12732669